The Journal of Practical Medicine >
Antiplatelet drugs and liver fibrosis
Received date: 2023-10-21
Online published: 2024-04-19
The essence of hepatic fibrosis is the imbalance of the formation and degradation of extracellular matrix in the liver tissue. Hepatic fibrosis is a necessary stage for the progression of various chronic liver diseases to cirrhosis. Early inhibition of the occurrence and development of hepatic fibrosis is very important in the treatment of liver diseases. Platelets release a variety of cytokines， which promote hepatocyte proliferation and liver parenchyma regeneration while activating endothelial cells， inducing leukocyte recruitment， aggravating microvascular dysfunction， and participating in the process of liver fibrosis. In this paper， the research progress of antiplatelet drugs in hepatic fibrosis is reviewed， in order to provide new diagnosis and treatment ideas for hepatic fibrosis.
Key words： hepatic fibrosis; antiplatelet; asprin; hepatic stellate cells
Xin ZHAO , Hui LI , Xiuxiu DENG , Yujing. TAO . Antiplatelet drugs and liver fibrosis[J]. The Journal of Practical Medicine, 2024 , 40(8) : 1083 -1087 . DOI: 10.3969/j.issn.1006-5725.2024.08.011
| 1 | ROEHLEN N， CROUCHET E， BAUMERT T F. Liver fibrosis： Mechanistic concepts and therapeutic perspectives［J］. Cells， 2020， 9（4）： 875. doi:10.3390/cells9040875 |
| 2 | AIROLA C， PALLOZZI M， CERRITO L， et al. Microvascular thrombosis and liver fibrosis progression： mechanisms and clinical applications［J］. Cells， 2023， 12（13）： 1712. doi:10.3390/cells12131712 |
| 3 | MAOUIA A， REBETZ J， KAPUR R， et al. The immune nature of platelets revisited［J］. Transfus Med Rev， 2020， 34（4）： 209-220. doi:10.1016/j.tmrv.2020.09.005 |
| 4 | YIN H， SHI A， WU J. Platelet-activating factor promotes the development of non-alcoholic fatty liver disease［J］. Diabetes Metab Syndr Obes， 2022， 15： 2003-2030. doi:10.2147/dmso.s367483 |
| 5 | POISSON J， LEMOINNE S， BOULANGER C， et al. Liver sinusoidal endothelial cells： Physiology and role in liver diseases［J］. J Hepatol， 2017， 66（1）： 212-227. doi:10.1016/j.jhep.2016.07.009 |
| 6 | DIDAMOONY M A， ATWA A M， AHMED L A. A novel mechanistic approach for the anti-fibrotic potential of rupatadine in rat liver via amendment of PAF/NF-?B p65/TGF-β1 and hedgehog/HIF-1α/VEGF trajectories［J］. Inflammopharmacology， 2023， 31（2）： 845-858. doi:10.1007/s10787-023-01147-7 |
| 7 | MEYER J， BALAPHAS A， FONTANA P， et al. Platelet interactions with liver sinusoidal endothelial cells and hepatic stellate cells lead to hepatocyte proliferation［J］. Cells， 2020， 9（5）： 1243. doi:10.3390/cells9051243 |
| 8 | FENG Y， DONG H， SUN B， et al. METTL3/METTL14 transactivation and m（6）a-dependent TGF-β1 translation in activated kupffer cells［J］. Cell Mol Gastroenterol Hepatol， 2021， 12（3）： 839-856. doi:10.1016/j.jcmgh.2021.05.007 |
| 9 | SINGH S， ANSHITA D， RAVICHANDIRAN V. MCP-1： Function， regulation， and involvement in disease［J］. Int Immunopharmacol， 2021， 101（Pt B）： 107598. doi:10.1016/j.intimp.2021.107598 |
| 10 | HAMMERICH L， TACKE F. Hepatic inflammatory responses in liver fibrosis［J］. Nat Rev Gastroenterol Hepatol， 2023， 20（10）： 633-646. doi:10.1038/s41575-023-00807-x |
| 11 | SUN Y， LIU B， XIE J， et al. Aspirin attenuates liver fibrosis by suppressing TGF-β1/Smad signaling［J］. Mol Med Rep， 2022， 25（5）： 181. doi:10.3892/mmr.2022.12697 |
| 12 | WANG T， FU X， JIN T， et al. Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma［J］. EBioMedicine， 2019， 45： 168-180. doi:10.1016/j.ebiom.2019.06.048 |
| 13 | JIANG Z G， FELDBRüGGE L， TAPPER E B， et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States［J］. Aliment Pharmacol Ther， 2016， 43（6）： 734-743. doi:10.1111/apt.13515 |
| 14 | SEVERO M D. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease［J］. Clin Gastroenterol Hepatol， 2020， 18（2）： 523. doi:10.1016/j.cgh.2019.05.034 |
| 15 | DU Z Q， ZHAO J Z， DONG J， et al. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy： A retrospective single-center study［J］. World J Gastroenterol， 2019， 25（28）： 3798-3807. doi:10.3748/wjg.v25.i28.3798 |
| 16 | LEE T Y， HSU Y C， TSENG H C， et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B［J］. JAMA Intern Med， 2019， 179（5）： 633-640. doi:10.1001/jamainternmed.2018.8342 |
| 17 | HILSCHER M B， SHAH V H. Small but mighty： Platelets in NASH and other chronic liver diseases［J］. Hepatology， 2020， 71（4）： 1501-1504. doi:10.1002/hep.31101 |
| 18 | CHEN C， CHEN J， WANG Y， et al. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation， apoptosis， cell cycle， and ECM-receptor interaction mediated by TGF-β/Smad signaling［J］. Phytomedicine， 2023， 110： 154626. doi:10.1016/j.phymed.2022.154626 |
| 19 | POUJOL-ROBERT A， BO?LLE P Y， CONTI F， et al. Aspirin may reduce liver fibrosis progression： Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation ［J］. Clin Res Hepatol Gastroenterol， 2014， 38（5）： 570-576. doi:10.1016/j.clinre.2014.07.004 |
| 20 | PAVLOVI? N， KOPSIDA M， GERWINS P， et al. Inhibiting P2Y12 in Macrophages induces endoplasmic reticulum stress and promotes an anti-tumoral phenotype［J］. Int J Mol Sci， 2020， 21（21）： 8177. doi:10.3390/ijms21218177 |
| 21 | CZAJKA P， PRZYBY?KOWSKI A， NOWAK A， et al. Antiplatelet drugs and liver fibrosis［J］. Platelets， 2022， 33（2）： 219-228. doi:10.1080/09537104.2021.1883574 |
| 22 | SCHWARZKOPF K， BOJUNGA J， RüSCHENBAUM S， et al. Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease［J］. Hepatol Commun， 2018， 2（12）： 1601-1609. doi:10.1002/hep4.1254 |
| 23 | HAN K， ZHANG Y， YANG Z. Cilostazol protects rats against alcohol-induced hepatic fibrosis via suppression of TGF-β1/CTGF activation and the cAMP/Epac1 pathway［J］. Exp Ther Med， 2019， 17（3）： 2381-2388. |
| 24 | MAHMOUD N I， MESSIHA B A S， SALEHC I G， et al. Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats［J］. Life Sci， 2019， 231： 116522. doi:10.1016/j.lfs.2019.05.078 |
| 25 | KRILL T， BROWN G， WEIDEMAN R A， et al. Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding， but no increased mortality［J］. Aliment Pharmacol Ther， 2017， 46（2）： 183-192. doi:10.1111/apt.14121 |
| 26 | SASSO R， ROCKEY D C. Anticoagulation therapy in patients with liver cirrhosis is associated with an increased risk of variceal hemorrhage［J］. Am J Med， 2019， 132（6）： 758-766. doi:10.1016/j.amjmed.2019.01.006 |
| 27 | IANNACONE M， GUIDOTTI L G. Immunobiology and pathogenesis of hepatitis B virus infection［J］. Nat Rev Immunol， 2022， 22（1）： 19-32. doi:10.1038/s41577-021-00549-4 |
| 28 | JANG H， LEE Y B， MOON H， et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis［J］. Hepatology， 2022， 76（2）： 492-501. doi:10.1002/hep.32380 |
| 29 | LEE C H， LEE Y B， MOON H， et al. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B［J］. Aliment Pharmacol Ther， 2023， 58（7）： 704-714. doi:10.1111/apt.17643 |
| 30 | TAN J L， SIDHU-BRAR S， WOODMAN R， et al. Regular aspirin use is associated with a reduced risk of hepatocellular carcinoma （HCC） in chronic liver Disease： a systematic review and meta-analysis［J］. J Gastrointest Cancer， 2023， 54（2）： 325-331. doi:10.1007/s12029-022-00842-y |
| 31 | SIMON T G， DUBERG A S， ALEMAN S， et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality［J］. N Engl J Med， 2020， 382（11）： 1018-1028. doi:10.1056/nejmoa1912035 |
/
| 〈 |
|
〉 |